Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection

Circulation

Volumn 90, Issue 4 I, 1994, Pages 2056-2069

  Lonn, Eva M ^a   Yusuf, Salim ^a,e   Jha, Prabhat ^a   Montague, Terrence J ^b   Teo, Koon K ^b   Benedict, Claude R ^c   Pitt, Bertram ^d  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e HAMILTON GENERAL HOSPITAL   (Canada)

Author keywords

angiotensin; atherosclerosis; coronary disease; enzymes

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; OXYGEN CONSUMPTION; OXYGEN SUPPLY; PRIORITY JOURNAL; PROPHYLAXIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; THROMBOSIS PREVENTION;

EID: 0028143970     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.90.4.2056     Document Type: Review

References (166)

1. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. Arch Intern Med. 1984;144:1947-1953.
2. Zusman RM. Renin- and non-renin-mediated antihypertensive actions of converting-enzyme inhibitors. Kidney Int. 1984;25: 969-983.
3. Tewksbury DA. Angiotensinogen: biochemistry and molecular biology. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. New York, NY: Raven Press; 1990:1197-1216.
4. The CONSENSUS Trial Group. Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
5. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
6. The SOLVD Investigators. Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327:685-691.
7. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669-677.
8. Pfeffer MA, Lamas GA, Vaughn DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilation after anterior myocardial infarction. N Engl J Med. 1988;319:80-86.
9. Sharpe N, Murphy J, Smith H, Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet. 1988;1:255-259.
10. Sharpe N, Smith H, Murphy J, Greaves S, Hart H, Gamble G. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet. 1991;337:872-876.
11. Dzau VJ. Angiotensin converting enzyme inhibitors and the cardiovascular system. J Hypertens. 1992;10(suppl 3):S3-S10.
12. Lindpainter K, Ganten D. The cardiac renin-angiotensin system: a synopsis of current experimental and clinical data. Acta Cordiol. 1991;46:385-397.
13. Gavras H, Brown JJ, Lever AF, Macadam RF, Robertson JIS. Acute renal failure, tubular necrosis and myocardial infarction induced into the rabbit by intravenous angiotensin-II. Lancet. 1971;122:1382-1388.
14. Dempsey P, McCallum L, Kent K, Cooper T. Direct myocardial effects of angiotensin II. Am J Physiol. 1971;220:477-481.
15. Krasney JA, Thompson JL, Lowe RF. Cardiac effects of angiotensin injections into perfused right coronary artery. Am J Physiol. 1967;213:134-138.
16. Kiowski W, Zuber M, Elsassar S, Erne P, Pfisterer M, Burkart F. Coronary vasodilation and improved myocardial lactate metabolism after angiotensin converting enzyme inhibition with enalapril in patients with congestive heart failure. Am Heart J. 1991;122: 1382-1388.
17. Gavras I, Gavras H. The use of ACE-inhibitors in hypertension. In: Kostis JB, DeFelice EA, eds. Angiotensin Converting Enzyme Inhibitors. New York, NY: Alan R Liss; 1987:93-122.
18. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of longterm therapy with captopril. Circulation. 1985;72:406-412.
19. Ertl G, Alexander RW, Kloner RA. Interaction between coronary occlusion and the renin-angiotensin system in the dog. Basic Res Cardiol. 1983;78:518-533.
20. Linz KW, Scholkens BA, Han Y-F. Beneficial effects of converting enzyme inhibitor ramipril, in ischemic rat hearts. J Cardiovasc Pharmacol. 1986;8(suppl 10):S91-S99.
21. Kiowski W, Burkart F. Effects of vasodilators on the coronary circulation in congestive heart failure. Am J Cardiol. 1988;62: 99E-103E.
22. Holz J, Busse R, Sommer O, Bassenge E. Dilatation of epicardial coronary arteries in conscious dogs induced by angiotensin-converting enzyme inhibition with enalaprilat. J Cardiovasc Pharmacol. 1987;9:348-355.
23. Van Gilst WH, Graeff PA, Scholtens E, deLangen CDJ, Wesseling H. Potentiation of isosorbide dinitrate-induced coronary dilation by captopril. J Cardiovasc Pharmacol. 1987;9:254-255.
24. Powers ER, Bannerman KS, Stone J, Reison DS, Escala EL, Kalischer A, Weiss MB, Sciacca RR, Cannon PJ. The effect of captopril on renal, coronary and systemic hemodynamics in patients with severe congestive heart failure. Am Heart J. 1982; 104:1203-1210.
25. Faxon DP, Creager MA, Halperin JL, Sussman HA, Gavras H, Ryan TJ. The effect of angiotensin converting enzyme inhibition on coronary blood flow and hemodynamics in patients without coronary artery disease. Int J Cardiol. 1982;2:251-262.
26. Magrini F, Shimizu M, Roberts N, Fouad FM, Tarazi RC, Zanchetti A. Converting-enzyme inhibition and coronary blood flow. Circulation. 1987;75(suppl I):I-168-I-174.
27. Magrini F, Reggiani P, Roberts N, Mezza R, Ciulla M, Zanchetti A. Effects of angiotensin and angiotensin blockade on coronary circulation and coronary reserve. Am J Med. 1988;84(suppl 3A): 55-60.
28. De Marco T, Daly PA, Liu M, Kayser S, Parmley WW, Chatterjee K. Enalaprilat, a new parenteral angiotensin converting enzyme inhibitor: rapid changes in systemic and coronary hemodynamics and humoral profile in congestive heart failure. J Am Coll Cardiol. 1987;9:1131-1138.
29. Rouleau JL, Chatterjee K, Benge W, Parmley WW, Hiramatsu B. Alterations in left ventricular function and coronary hemodynamics with captopril, hydralazine and prazosin in chronic ischemic heart failure: a comparative study. Circulation. 1982;65:671-678.
30. Chatterjee K, Rouleau JL, Parmley WW. Hemodynamic effects of captopril in chronic heart failure. Br Heart J. 1982;47:233-238.
31. Halperin JL, Faxon DP, Creager MA, Bass TA, Melidossian CD, Gavras H, Ryan TJ. Coronary hemodynamic effects of angiotensin inhibition by captopril and teprotide in patients with congestive heart failure. Am J Cardiol. 1982;50:967-972.
32. Wenting GJ, Man in 't Veld AJ, Woittiez AJ, Boosma F, Laird-Meeter K, Simoons ML, Hugenholz PG, Schalekamp MADH. Acute and chronic heart failure: correlation with plasma levels of noradrenaline, renin and aldosterone. Br Heart J. 1983;49:65-76.
33. Mattiolli G, Ricci S, Rigo R, Roberto R, Fusaro MT, Cappello C. Effects of captopril in heart failure complicating acute myocardial infarction and persistence of acute hemodynamic effect in chronic heart failure after 3 years of treatment. Postgrad Med J. 1986; 62(suppl I):164-166.
34. Schultheiss HP, Ullrich M, Schindler M, Schulze SK, Strauer BE. The effect of ACE inhibition on myocardial energy metabolism. Eur Heart J. 1990;11(suppl B):116-122.
35. Levy BI, Michel JB, Salzman JL, Poitevin P, Devissaguet M, Scalbert E, Safar ME. Long-term effects of angiotensin-converting enzyme inhibition on the arterial wall of adult spontaneously hypertensive rats. Am J Cardiol. 1993;71:8E-16E.
36. Karam R, Healy B, Wicker P. Coronary reserve is depressed in postmyocardial infarction reactive hypertrophy. Circulation. 1990; 81:238-246.
37. Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease: the Framingham Study. Ann Intern Med. 1970;72: 813-822.
38. Kannel WB, Schatzkin A. Sudden death: lessons from subsets in population studies. J Am Coll Cardiol. 1985;5(suppl):141B-149B.
39. McLenachan JM, Henderson E, Morris KI, Dargie HJ. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med. 1987;317:787-792.
40. Levy D, Garrison MS, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
41. Dunn FG, Oigman W, Ventura HO, Messerli FH, Kobrin I. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol. 1984;53:105-108.
42. Garavaglia GE, Messerli FH, Nunez BD, Schmieder RE, Frohlich ED. Immediate and short-term cardiovascular effects of a new converting enzyme inhibitor (lisinopril) in essential hypertension. Am J Cardiol. 1988;62:912-916.
43. Ventura HO, Frohlich ED, Messerli FH, Kobrin I, Kardon MB. Cardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertension. Am J Cardiol. 1985;55:1023-1026.
44. Mujais SK, Fouad FM, Tarazi RC. Reversal of left ventricular hypertrophy with captopril: heterogenicity of response among hypertensive patients. Clin Cardiol. 1983;6:595-602.
45. Dal Palù C, Pessina AC, Pagnan A, Pauleto P, Lusiani L, Ronisvalle G, Ronisvalle G, Muiesan G, Rosei EA, Corea L, Bentivoglio M. Effect of captopril on left ventricular mass and function in hypertensive patients and in the rat. Postgrad Med J. 1986;62(suppl 1):85-89.
46. Nakashima Y, Fouad FM, Tarazi RC. Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol. 1984;53:1044-1049.
47. Weber KT, Janicki JS. Angiotensin and the remodelling of the myocardium. Br J Clin Pharmacol. 1989;28(suppl):141S-150S.
48. Tan L-P, Brilla C, Weber KT. Prevention of structural changes in the heart in hypertension by angiotensin converting enzyme inhibition. J Hypertens. 1992;(suppl 1):S31-S34.
49. Linz W, Scholkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens. 1989;11: 1325-1350.
50. Lindpainter K, Ganten D. The cardiac renin-angiotensin system: a synopsis of current experimental and clinical dala.Acta Cardiol. 1991;46:385-397.
51. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation. 1993;87:1816-1828.
52. Drexler H, Lindpainter K, Lu W, Schieffer B, Ganten D. Transient increase in the expression of cardiac angiotensinogen in a rat model of infarction and failure. Circulation. 1989;80(suppl II):II-459. Abstract.
53. Bauwens FR, Duprez DA, De Buyzere ML, De Backer TL, Kaufman JM, Hoecke JV, Vermenlen A, Clement DL. Influence of the arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol. 1991;68:925-929.
54. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
55. Bickerton RK, Buckley JP. Evidence for a central mechanism in angiotensin induced hypertension. Proc Soc Exp Biol Med. 1961; 106:834-836.
56. Ferrario CM, Gildenberg PL, McCubbin JW. Cardiovascular actions of angiotensin mediated by the central nervous system. Circ Res. 1972;30:257-262.
57. Zimmerman BG. Evaluation of peripheral and central components of action of angiotensin on the sympathetic nervous system. J Pharmacol Exp Ther. 1967;158:1-10.
58. Zimmerman BG, Sybertz EJ, Wong PC. Interaction between sympathetic and renin-angiotensin system. Hypertension. 1984;2: 581-587.
59. Ziogas J, Story DF, Rand MJ. Effects of locally generated angiotensin II on noradrenergic transmission in guinea pig isolated atria. Eur J Pharmacol. 1985;106:11-18.
60. Lanier SM, Malik KU. Attenuation by prostaglandins of the facilitatory effect of angiotensin II at adrenergic prejunctional sites in the isolated Krebs-perfused rat heart. Circ Res. 1982;51: 594-601.
61. Hughes J, Roth RH. Evidence that angiotensin enhances transmitter release during sympathetic nerve stimulation. Br J Pharmacol. 1971;41:239-255.
62. Goldsmith SR, Haskins GJ, Miller E. Angiotensin II and sympathetic activity in patients with congestive heart failure. J Am Coll Cardiol. 1993;21:1107-1113.
63. Richard DP, Benedict CR, Kronenberg MW, Udelson JE, Stewart D, Kilcoyne L, Dolan N, Yusuf S, Konstam MA, for the SOLVD Investigators. Effects of long-term enalapril on adrenergic activity and sensitivity during exercise in patients with left ventricular dysfunction. Circulation. 1993;88(pt 2):I-293. Abstract.
64. Gilbert EM, Sandoval A, Larrabee P, Renlund DG, O'Connell JB, Bristow MR. Lisinopril lowers cardiac adrenergic drive and increases β-receptor density in the failing human heart. Circulation. 1993;88:472-480.
65. Ertl G, Kloner RA, Alexander RW, Braunwald E. Limitation of experimental infarct size by an angiotensin converting enzyme inhibitor. Circulation. 1982;66:1249-1255.
66. Lefer AM, Peck RC. Cardioprotective effects of enalapril in acute myocardial ischemia. Pharmacology. 1984;29:61-69.
67. Sweet CS. Issues surrounding a local cardiac renin system and the beneficial actions of angiotensin-converting enzyme inhibitors in ischemic myocardium. Am J Cardiol. 1990;65:111-113.
68. Liang C, Gavras I, Black J, Sherman LG, Hood WB. Renin-angiotensin enzyme inhibitors in acute myocardial infarction in dogs. Circulation. 1982;66:1249-1255.
69. Daniell HB, Carson RR, Ballard KD, Thomas GR, Privitera PJ. Effect of captopril on limiting infarct size in conscious dogs. J Cardiovasc Pharmacol. 1984;6:1043-1047.
70. Westlin W, Mullane K. Does captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals? Circulation. 1988;77(suppl I):I-30. Abstract.
71. Przyklenk K, Kloner RA. Acute effects of hydralazine and enalapril on contractile function of post-ischemic stunned myocardium. Am J Cardiol. 1987;60:934-936.
72. Przyklenk K, Kloner RA. Relationships between structure and effects of ACE inhibitors: comparative effects in myocardial ischemia/reperfusion injury. Br J Clin Pharmacol. 1989;28:167S-175S.
73. Van Gilst VM, deGraeff PA, Wesseling H, deLangen CDJ. Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril and HOE498. J Cardiovasc Pharmacol. 1986;8:722-728.
74. Linz W, Martorana PA, Scholkens BA. Local inhibition of bradykinin degradation in ischemic hearts. J Cardiovasc Pharmacol. 1990;15(suppl 6):S99-S109.
75. Kigma JH, deGraeff PA, Van Gilst WH, Binsbergen E, deLangen CDJ, Wesseling H. Effects of intravenous captopril on inducible sustained ventricular tachycardia one week after experimental infarction in anesthetized pig. Postgrad Med J. 1986;62(suppl I):159-163.
76. Pi X, Chen X. Captopril and ramiprilat protect against free radical injury in isolated working rat heart. J Mol Cell Cardiol. 1989;21:1261-1271.
77. Mak IT, Freedman AM, Dickens BF, Weglicki WB. Protective effects of sulfhydryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. Biochem Pharmacol. 1990;40:2169-2175.
78. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Anti-atherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1990;15:327-331.
79. Chobanian AV. The effects of ACE inhibitors and other antihypertensive drugs on cardiovascular risk factors and atherogenesis. Clin Cardiol. 1990;13:VII-43-VII-48.
80. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol. 1990;15:S65-S72.
81. Rolland PH, Charpiot P, Friggi A, Piquet P, Barlatier A, Scalbert E, Bodard H, Tranier P, Mercier C, Luccioni R, Garcon D. Effects of angiotensin-converting enzyme inhibition with perindolol on hemodynamics, arterial structure, and wall rheology in the hindquarters of atherosclerotic mini-pigs. Am J Cardiol. 1993; 71:22E-27E.
82. Powell JS, Clozel JP, Muller RKM, Kuhn H, Hefti F, Hosang M, Baumgartner HR. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989;245:186-188.
83. Bilazarian SD, Currier JW, Haudenschild C, Heyman D, Powell J, Ryan TJ, Faxon DP. Angiotensin converting enzyme inhibition reduces restenosis in experimental angioplasty. Circulation. 1990; 82(suppl II):II-297. Abstract.
84. Michel JB, Plissonier D, Bruneval P. Effect of perindopril on the immune arterial wall remodeling in the rat model of arterial graft rejection. Am J Med. 1992;92(suppl 4B):39S-46S.
85. Rakugi H, Jacob HJ, Krieger JE, Ingelfinger JR, Pratt RE. Vascular injury induces angiotensinogen gene expression in the media and neointima. Circulation. 1993;87:283-290.
86. Lam JYT, Bourassa MG, Blaine L, Lachapelle C. Can cilazapril reduce the development of atherosclerotic changes in the balloon injured porcine carotid arteries? Circulation. 1990;82(suppl III): III-429. Abstract.
87. Churchill DA, Siegel CO, Dougherty KG, Raizner A, Minor ST. Failure of enalapril to reduce coronary restenosis in a swine model. Circulation. 1991;84(suppl II):II-298. Abstract.
88. Huber KC, Schwartz RS, Edwards WD, Camrad AR, Bailey KR, Jorgensen MA, Holmes DR Jr. Effects of angiotensin converting enzyme inhibition on neointimal proliferation in a porcine coronary injury model. Am Heart J. 1993;125:695-701.
89. The Multicenter European Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR randomized, double blind placebo-controlled trial. Circulation. 1992;86:100-110.
90. The MARCATOR Investigators. Angiotensin converting enzyme inhibition and restenosis. Circulation. 1992;4(suppl I):I-53. Abstract.
91. Campbell-Boswell M, Robertson AL. Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro. Exp Mol Pathol. 1981;35:265-276.
92. Geisterfer AAT, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res. 1988;62:749-756.
93. Daemen MJAP, Lombardi DM, Bosman FT, Schwatz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 1991;68:450-456.
94. Katz AM. Angiotensin II: hemodynamic regulator or growth factor? J Mol Cell Cardiol. 1990;22:739-747.
95. Dzau VJ. Cardiac renin-angiotensin system: molecular and functional aspects. Am J Med. 1988;84(suppl 3A):22-27.
96. Re RN. The cellular biology of angiotensin: paracrine, autocrine and intracrine actions in cardiovascular tissues. J Mol Cell Cardiol. 1989;21(suppl V):63-69.
97. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth-factor A chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83:1419-1424.
98. Naftilan AJ, Pratt RE, Eldridge CS, Lin HL, Dzau VJ. Angiotensin II induces c-fos expression in smooth muscle via transcriptional control. Hypertension. 1989;13:706-711.
99. Taubman MB, Bradford CB, Izumo S, Tsuda T, Alexander RW, Nadal-Ginard B. Angiotensin II induces c-fos mRNA in aortic smooth muscle. J Biol Chem. 1989;264:526-530.
100. Kawahara Y, Sunako M, Tsuda T, Fukuzaki H, Fukumoto Y, Takai Y. Angiotensin II induces expression of c-fos gene through protein kinase C activation and calcium ion mobilization in cultured vascular smooth muscle cells. Biochem Biophys Res Commun. 1988;150:52-59.
101. Paquet J-L, Baudouin-Legros M, Brunelle G, Meyer P. Angiotensin II-induced proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens. 1990;8:565-572.
102. Naftilan AJ, Gilliland GK, Eldridge CS, Kraft AS. Induction of the proto-oncogene c-jun by angiotensin II. Mol Cell Biol. 1990; 10:5536-5540.
103. Lyall F, Morton JJ, Gillespie D. Angiotensin II stimulates c-jun expression in cultured vascular smooth muscle cells: superinduction by emetine. Eur J Intern Med. 1992;2:271-273.
104. Scott-Burden T, Resink TJ, Hahn AWA, Buhler FR. Induction of thrombospondin expression in vascular smooth muscle cells by angiotensin II. J Cardiovasc Pharmacol. 1990;16(suppl 7):17-20.
105. Powell JS, Rouge M, Muller RKM, Baumgartner HR. Cilazapril suppresses myointimal proliferation after vascular injury: effects on growth factor induction and vascular smooth muscle cells. Basic Res Cardiol. 1991;86(suppl I):65-74.
106. Powell JS, Muller RKM, Rouge M, Kuhn H, Hefti F, Baumgartner HR. The proliferative response to vascular injury is suppressed by angiotensin-converting enzyme inhibition. J Cardiovasc Pharmacol. 1990;16(suppl 4):S42-S49.
107. Farber HW, Center DM, Rounds S, Danilov SM. Components of the angiotensin system cause release of neutrophil chemoattractant from cultured bovine and human endothelial cells. Eur Heart J. 1990;11(suppl B):100-107.
108. Clozel M, Kuhn H, Hefti F, Baumgartner HR. Endothelial dysfunction and subendothelial monocyte macrophages in hypertension: effect of angiotensin converting enzyme inhibition. Hypertension. 1991;18:132-141.
109. Clozel M, Kuhn H, Hefti F. Effects of angiotensin converting enzyme inhibitors and of hydralazine on endothelial function in hypertensive rats. Hypertension. 1990;16:532-540.
110. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med. 1986;314:488-499.
111. Bell L, Madri JA. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol. 1990; 137:7-12.
112. Becker RHA, Wiemer G, Linz W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol. 1991;18(suppl 2):110-115.
113. Shulz PJ, Raij L. Effects of antihypertensive agents on endothelium-dependent and endothelium-independent relaxations. Br J Clin Pharmacol. 1989;28:S151-S157.
114. Ontkean MT, Gay R, Greenberg B. Effects of chronic captopril therapy on endothelium derived relaxing factor activity in heart failure. J Am Coll Cardiol. 1992;19(suppl A):768-774.
115. Erdos EG. Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol. 1990;15(suppl 6):S20-S24.
116. Pohl U. Role of endothelium-derived nitric oxide in the control of local blood flow under physiological and pathophysiological conditions. Can J Cardiol. 1993;9(suppl C):6C-11C.
117. Wiemer G, Bernward A, Scholkens A, Becker RHA, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension. 1991;18:558-563.
118. Dohi Y, Hahn AWA, Boulanger CM, Buhler FR, Luscher TF. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension. 1992;19:131-137.
119. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension. 1993;21:929-933.
120. Luscher TF, Boulanger CM, Dohi Y, Yang Z. Endothelium-derived contracting factors. Hypertension. 1992;19:117-130.
121. Turlapaty PDMV, Altura BM. Magnesium deficiency produces spasms of the coronary arteries: relationships to etiology of sudden ischemic heart disease. Science. 1980;208:198-200.
122. Eisenberg MJ. Magnesium deficiency and sudden death. Am Heart J. 1992;124:544-549.
123. James IM, Dickenson EJ, Burgoyne W, Jeremy JY, Barrados MA, Mikhailidis DP, Dandona P. Treatment of hypertension with captopril: preservation of regional blood flow and reduced platelet aggregation. J Hum Hypertens. 1988;2:21-25.
124. Someya N, Morotomi Y, Kodama K, Kida O, Higa T, Kondo K, Tanaka K. Suppressive effects of captopril on platelet aggregation in essential hypertension. J Cardiovasc Pharmacol. 1984;6: 840-843.
125. Vaughan DE, Shen C, Lazos SA. Angiotensin II induces secretion of plasminogen activator inhibitor (PAI-1) in vitro. Circulation. 1992;86(suppl I):I-557. Abstract.
126. Olson JA Jr, Shiverick KT, Ogilvie S, Buhi WC, Raizada MK. Angiotensin II induces secretion of plasminogen activator inhibitor 1 and a tissue metalloprotease inhibitor-related protein from rat brain astrocytes. Neurobiology. 1991;88:1928-1932.
127. Luskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb. 1989;9:87-115.
128. Ridker PM. An epidemiologic assessment of thrombotic risk factors for cardiovascular disease. Curr Opin Lipidol. 1992;3: 285-290.
129. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation. 1993;87:1969-1973.
130. Chobanian AV, Brecher PI, Handenschild CC. The effects of hypertension and antihypertensive therapy on atherosclerosis. Hypertension. 1986;8(suppl I):I-15-I-21.
131. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke and coronary heart disease, I: effects of prolonged differences in blood pressure: evidence from nine prospective observational studies corrected for the regression dilution bias. Lancet. 1989; 335:765-774.
132. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke and coronary heart disease, II: effect of short-term reductions in blood pressure: an overview of randomized drug trials in an epidemiological context. Lancet. 1990; 335:827-838.
133. Lardinois CK, Neuman SL. The effects of antihypertensive agents on serum lipids and lipoproteins. Arch Intern Med. 1988;148: 1280-1288.
134. Costa FV, Borghi C, Mussi A, Ambrosioni E. Hypolipidemic effects of long-term antihypertensive treatment with captopril. Am J Med. 1988;84(suppl 3A):159-161.
135. Perani G, Muggia C, Martignoni A, Bongarzoni A, Radaelli A, Tesla F, Finardi G. Increase in plasma HDL-cholesterol in hypertensive patients treated with enalapril. Clin Ther. 1987;9:635-639.
136. Wiedman P, Uelinge DE, Gerber A. Antihypertensive treatment and serum lipoproteins. J Hypertens. 1984;3:297-306.
137. Pollane T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril in glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989; 321:868-873.
138. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Buhler FR. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med. 1972;286: 441-449.
139. Meade TW, Imeson JD, Gordon D, Peart WS. The epidemiology of plasma renin. Clin Sci. 1983;64:273-280.
140. Alderman MH, Madhavan SH, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324:1098-1104.
141. Dzau VJ. Renin and myocardial infarction in hypertension. N Engl J Med. 1991;324:1128-1130.
142. Meade TW, Cooper JA, Peart WS. Plasma renin activity and ischemic heart disease. N Engl J Med. 1993;329:616-619.
143. Cambien F, Poirier O, Lecerf L, Evans A, Cambou J-P, Arveiler D, Luc G, Bard J-M, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641-644.
144. Tiret L, Kee F, Poirier O, Nicaud V, Lecerf L, Evans A, Cambou J-P, Arveilier D, Gerald L, Amouyel P, Cambien F. Deletion polymorphism in angiotensin-converting enzyme gene associated with parenteral history of myocardial infarction. Lancet. 1993;341: 991-992.
145. Marian AJ, Yu O-T, Workman R, Greve G, Roberts R. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet. 1993;342: 1085-1086.
146. Raynolds MV, Bristow MR, Bush EW, Abraham WT, Lowes BD, Zisman LS, Taft CS, Perryman MB. Angiotensin-converting enzyme DD genotype in patients with ischemic or idiopathic dilated cardiomyopathy. Lancet. 1993;342:1073-1075.
147. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
148. Yusuf S, Collins R, Peto R, Furberg C, Stampfer MJ, Goldhaber SZ, Hennekins CH. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J. 1985;6:556-585.
149. Rutherford JD, Pfeffer MA, Moyé LA, Davis BR, Flaker GC, Kowey PR, Lamas GA, Miller HS, Packer M, Rouleau JL, Braunwald E, on behalf of the SAVE Investigators. Effects of captopril on ischemic effects after myocardial infarction. Circulation. In press.
150. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340:1173-1178.
151. Francis G, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang C-S, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729.
152. Benedict CR, Johnstone DE, Weiner D, Bourassa MG, Bittner V, Kay R, Kirlin P, Greenberg B, Kohn RM, Nicklas JM, McIntyre K, Quiñones MA, Yusuf S, for the SOLVD Investigators. Relationship of neurohormonal activation to clinical variables and degree of ventricular dysfunction: a report from the registry of Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1994; 23:1410-1420.
153. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992;327:678-684.
154. ISIS Collaborative Group. ISIS-4: randomised study of oral captopril in over 50,000 patients with suspected acute myocardial infarction. Circulation. 1993;88(part 2):I-394. Abstract.
155. GISSI Collaborative Group. Oral presentation at the 66th Scientific Sessions of the American Heart Association, November 1993.
156. The Chinese Captopril Trial. Oral presentation at the 66th Scientific Sessions of the American Heart Association, November 1993.
157. Texter M, Lees RS, Pitt B, Dinsmore RE, Uprichard ACG. The Quinapril Ischemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention. Cardiovasc Drugs Ther. 1993;7:273-282.
158. Daly P, Rouleau JL, Cousineau D, Burgess JH. Acute effects of captopril on the coronary circulation of patients with hypertension and angina. Am J Med. 1984;76(suppl B):111-115.
159. Daly P, Mettauer P, Rouleau JL, Cousineau D, Burgess JH. Lack of reflex increase in myocardial sympathetic tone after captopril: potential antianginal effect. Circulation. 1985;71:317-325.
160. Akhras F, Jackson G. Captopril as monotherapy for stable angina and hypertension. Eur Heart J. 1988;9(suppl 1):2. Abstract.
161. Strozzi C, Portaluppi F, Cocco G, Urso L. Ergometric evaluation of the effects of enalapril maleate in normotensive patients with stable angina. Clin Cardiol. 1988;11:246-249.
162. Strozzi C, Cocco G, Portaluppi F, Portaluppi F, Urso L, Alfiero R, Tarsini MT, Montanari L, Al Yassini K, Rizz A. Effects of captopril on the physical work capacity of normotensive patients with stable effort angina pectoris. Cardiology. 1987;74:226-228.
163. Bussman WD, Goerke S, Schneider W, Kaltenbach M. Angiotensin-Converting-Enzym-Hemmer bei Angina pectoris. Dtsch Med Wochenschr. 1988;113:548-550.
164. Gibbs JSR, Crean PA, Mockus L, Wright C, Sutton GC, Fox KM. The variable effects of angiotensin converting enzyme inhibition on myocardial ischaemia in chronic stable angina. Br Heart J. 1989;62:112-117.
165. Cleland JGF, Henderson E, McLenachan JM, Findlay IN, Dargie HJ. Effect of captopril, an angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure. J Am Coll Cardiol. 1991;17:733-739.
166. Sogaard P, Gotzsche C-O, Ravkilde J, Thygesen K. Effects of captopril on ischemia and dysfunction of the left ventricle after myocardial infarction. Circulation. 1993;87:1093-1099.